NCT02374489 2018-04-05
A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
National Health Research Institutes, Taiwan
Phase 2 Terminated
National Health Research Institutes, Taiwan
Criterium, Inc.